Other included tumor endothelial and stromal antigens

The term 'Other included tumor endothelial and stromal antigens' refers to a heterogeneous group of molecular targets located within the tumor microenvironment (TME) rather than on the malignant cells themselves (Source: PMC6769158). This category typically includes proteins expressed by tumor-associated endothelial cells, which facilitate angiogenesis and blood supply, as well as stromal cells such as cancer-associated fibroblasts (CAFs) that provide structural support and facilitate immune evasion (Source: PubMed 10948528). Because it is a collective designation used in clinical trial databases and oncology research, it does not represent a single biological entity or a specific receptor. Instead, it serves as a catch-all for various antigens like Endosialin (CD248), Fibroblast Activation Protein (FAP), and other tumor endothelial markers (TEMs) (Source: UniProt Q9HCU0, Q12884). Consequently, there is no single mechanism of action or specific drug associated with this term, as it encompasses a wide array of therapeutic strategies aimed at disrupting the tumor's supportive infrastructure. It is considered an 'incorrect' target designation for precise pharmacological classification due to its lack of molecular specificity.

Other names

Tumor microenvironment antigensTumor-associated stromal antigensTumor endothelial markers

Not applicable as this is a collective category of diverse molecular targets rather than a single entity.